Amarin Stock Surges on Heart Drug Study
Amarin (AMRN) shares are surging this morning on positive results for the company’s fish-oil treatment for people at risk of heart disease.The drug AMR101 lowered levels of triglyceride (a fat-like substance found in blood) without increasing bad cholesterol in patients on a statin therapy such as Lipitor the company said. The drug was rejected by US Food and Drug Administration officials in 2007 because it increased LDL or bad cholesterol in some patients.Shares of the company shot up 80% to $15.78 in morning trading Monday. They have increased eightfold in the past year.Amarin plans to apply for US approval ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here